Association for Molecular Pathology v. Myriad Genetics, Inc.
E390992
Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Association for Molecular Pathology v. Myriad Genetics, Inc. canonical | 3 |
| AMP v. Myriad | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T3822024 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Association for Molecular Pathology v. Myriad Genetics, Inc. Context triple: [October Term 2012, includesCase, Association for Molecular Pathology v. Myriad Genetics, Inc.]
-
A.
Myriad Genetics
Myriad Genetics is a biotechnology company best known for developing and commercializing genetic tests, particularly for assessing inherited cancer risk.
-
B.
NFIB v. Sebelius
NFIB v. Sebelius is the landmark 2012 U.S. Supreme Court case that largely upheld the Affordable Care Act, notably ruling that its individual mandate could be sustained under Congress’s taxing power.
-
C.
Burwell v. Hobby Lobby Stores, Inc.
Burwell v. Hobby Lobby Stores, Inc. is a 2014 U.S. Supreme Court case in which the Court held that closely held for-profit corporations can claim religious exemptions from certain federal regulations under the Religious Freedom Restoration Act.
-
D.
King v. Burwell
King v. Burwell is a landmark 2015 U.S. Supreme Court case that upheld the availability of federal tax credits for health insurance purchased on exchanges under the Affordable Care Act.
-
E.
Argersinger v. Hamlin
Argersinger v. Hamlin is a 1972 U.S. Supreme Court case that extended the right to counsel to defendants in misdemeanor cases that may result in imprisonment.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Association for Molecular Pathology v. Myriad Genetics, Inc. Target entity description: Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
-
A.
Myriad Genetics
Myriad Genetics is a biotechnology company best known for developing and commercializing genetic tests, particularly for assessing inherited cancer risk.
-
B.
NFIB v. Sebelius
NFIB v. Sebelius is the landmark 2012 U.S. Supreme Court case that largely upheld the Affordable Care Act, notably ruling that its individual mandate could be sustained under Congress’s taxing power.
-
C.
Burwell v. Hobby Lobby Stores, Inc.
Burwell v. Hobby Lobby Stores, Inc. is a 2014 U.S. Supreme Court case in which the Court held that closely held for-profit corporations can claim religious exemptions from certain federal regulations under the Religious Freedom Restoration Act.
-
D.
King v. Burwell
King v. Burwell is a landmark 2015 U.S. Supreme Court case that upheld the availability of federal tax credits for health insurance purchased on exchanges under the Affordable Care Act.
-
E.
Argersinger v. Hamlin
Argersinger v. Hamlin is a 1972 U.S. Supreme Court case that extended the right to counsel to defendants in misdemeanor cases that may result in imprisonment.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
United States Supreme Court case
ⓘ
biotechnology law case ⓘ patent law case ⓘ |
| arguedDate | 2013-04-15 ⓘ |
| citation | 569 U.S. 576 ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| court | Supreme Court of the United States ⓘ |
| decisionDate | 2013-06-13 ⓘ |
| decisionType | unanimous decision ⓘ |
| docketNumber | 12-398 ⓘ |
| fullName | Association for Molecular Pathology v. Myriad Genetics, Inc. self-link ⓘ |
| holding |
Myriad’s patents on naturally occurring BRCA1 and BRCA2 gene sequences are invalid
ⓘ
cDNA is patent eligible because it is not naturally occurring ⓘ naturally occurring DNA segments are products of nature and not patent eligible merely because they have been isolated ⓘ |
| impact |
clarified patent eligibility of DNA-related inventions
ⓘ
increased competition in genetic testing for BRCA mutations ⓘ limited the scope of gene patents in the United States ⓘ reshaped patent strategies in biotechnology ⓘ |
| issue |
patent eligibility of complementary DNA (cDNA)
ⓘ
patent eligibility of human genes ⓘ patent eligibility of isolated DNA ⓘ |
| legalPrinciple |
laws of nature, natural phenomena, and abstract ideas are not patentable
ⓘ
products of nature are not patent eligible under 35 U.S.C. § 101 ⓘ |
| legalSubject |
biotechnology
ⓘ
genetic testing ⓘ intellectual property ⓘ patent law ⓘ |
| lowerCourt | United States Court of Appeals for the Federal Circuit ⓘ |
| lowerCourtCitation | 689 F.3d 1303 (Fed. Cir. 2012) ⓘ |
| lowerCourtDecisionDate | 2012-08-16 ⓘ |
| majorityOpinionBy | Clarence Thomas ⓘ |
| petitioner |
American Civil Liberties Union
ⓘ
Association for Molecular Pathology ⓘ Public Patent Foundation ⓘ |
| relatedTo |
In re Chakrabarty
ⓘ
surface form:
Diamond v. Chakrabarty
Mayo Collaborative Services v. Prometheus Laboratories, Inc. ⓘ |
| respondent |
Myriad Genetics
ⓘ
surface form:
Myriad Genetics, Inc.
United States Patent and Trademark Office ⓘ University of Utah Research Foundation ⓘ |
| shortName |
Association for Molecular Pathology v. Myriad Genetics, Inc.
self-linksurface differs
ⓘ
surface form:
AMP v. Myriad
|
| statuteInterpreted | 35 U.S.C. § 101 ⓘ |
| subjectMatter |
BRCA1 gene
ⓘ
BRCA2 gene ⓘ breast cancer susceptibility genes ⓘ ovarian cancer susceptibility genes ⓘ |
| topic |
gene patenting
ⓘ
medical diagnostics patents ⓘ |
| vote | 9-0 ⓘ |
| yearDecided | 2013 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Association for Molecular Pathology v. Myriad Genetics, Inc. Description of subject: Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.
Association for Molecular Pathology v. Myriad Genetics, Inc.
→
fullName
→
Association for Molecular Pathology v. Myriad Genetics, Inc.
self-link
ⓘ
Association for Molecular Pathology v. Myriad Genetics, Inc.
→
shortName
→
Association for Molecular Pathology v. Myriad Genetics, Inc.
self-linksurface differs
ⓘ
this entity surface form:
AMP v. Myriad